ST Pharm Co.,Ltd. (237690.KQ)
KRW 84900.0
(-4.61%)
KRW 84900.0
(-4.61%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 106.62 Billion KRW | 28.04% |
| 2022 | 83.28 Billion KRW | 54.47% |
| 2021 | 53.91 Billion KRW | 225.56% |
| 2020 | 16.56 Billion KRW | 692.36% |
| 2019 | -2.79 Billion KRW | -235.72% |
| 2018 | 2.05 Billion KRW | -97.4% |
| 2017 | 79.14 Billion KRW | -14.83% |
| 2016 | 92.92 Billion KRW | 81.77% |
| 2015 | 51.12 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 17.73 Billion KRW | -54.94% |
| 2024 Q2 | 14.01 Billion KRW | -20.99% |
| 2024 Q3 | 61.2 Billion KRW | 60.34% |
| 2023 Q2 | 20.89 Billion KRW | -13.68% |
| 2023 Q3 | 22.55 Billion KRW | 7.95% |
| 2023 Q4 | 39.36 Billion KRW | 74.54% |
| 2023 FY | 106.62 Billion KRW | 28.04% |
| 2023 Q1 | 24.2 Billion KRW | -15.5% |
| 2022 Q1 | 15.48 Billion KRW | 14.33% |
| 2022 Q4 | 28.64 Billion KRW | 42.56% |
| 2022 FY | 83.28 Billion KRW | 54.47% |
| 2022 Q3 | 20.09 Billion KRW | 5.43% |
| 2022 Q2 | 19.05 Billion KRW | 23.05% |
| 2021 Q4 | 13.54 Billion KRW | -34.67% |
| 2021 FY | 53.91 Billion KRW | 225.56% |
| 2021 Q3 | 20.73 Billion KRW | 28.19% |
| 2021 Q2 | 16.17 Billion KRW | 333.25% |
| 2021 Q1 | 3.73 Billion KRW | -71.54% |
| 2020 Q2 | 4.74 Billion KRW | 2365.93% |
| 2020 Q3 | 694.99 Million KRW | -85.35% |
| 2020 Q4 | 13.11 Billion KRW | 1787.61% |
| 2020 FY | 16.56 Billion KRW | 692.36% |
| 2020 Q1 | -209.37 Million KRW | -162.39% |
| 2019 Q4 | 335.61 Million KRW | -71.16% |
| 2019 Q2 | 12.31 Million KRW | 100.36% |
| 2019 Q1 | -3.39 Billion KRW | 43.38% |
| 2019 FY | -2.79 Billion KRW | -235.72% |
| 2019 Q3 | 1.16 Billion KRW | 9351.4% |
| 2018 Q1 | 4.37 Billion KRW | -77.99% |
| 2018 Q3 | -4.56 Billion KRW | -152.34% |
| 2018 FY | 2.05 Billion KRW | -97.4% |
| 2018 Q2 | 8.72 Billion KRW | 99.41% |
| 2018 Q4 | -5.99 Billion KRW | -31.11% |
| 2017 Q4 | 19.88 Billion KRW | 39.38% |
| 2017 Q3 | 14.26 Billion KRW | -38.01% |
| 2017 FY | 79.14 Billion KRW | -14.83% |
| 2017 Q2 | 23.01 Billion KRW | 2.55% |
| 2017 Q1 | 22.44 Billion KRW | 8.01% |
| 2016 Q4 | 20.78 Billion KRW | -15.62% |
| 2016 Q2 | 35.01 Billion KRW | 182.94% |
| 2016 FY | 92.92 Billion KRW | 81.77% |
| 2016 Q1 | 12.37 Billion KRW | -17.99% |
| 2016 Q3 | 24.62 Billion KRW | -29.67% |
| 2015 Q3 | 20.98 Billion KRW | 118.92% |
| 2015 Q4 | 15.09 Billion KRW | -28.08% |
| 2015 Q2 | 9.58 Billion KRW | 0.0% |
| 2015 FY | 51.12 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | 94.48 Billion KRW | -12.851% |
| Hyundai Bioscience Co., Ltd. | 5.04 Billion KRW | -2015.157% |
| ABL Bio Inc. | 65.5 Billion KRW | -62.79% |
| Cellid, Co., Ltd. | -2.66 Billion KRW | 4103.217% |